VivoSeq
Oncology

Glioblastoma Multiforme

256

Pipeline Programs↗

25

Active Trials↗

89

Companies Involved↗

Glioblastoma Multiforme is a highly competitive landscape with 256 programs across 89 companies. The most active players are Arcus Biosciences, Adnexus, A Bristol-Myers Squibb R&D Company, Shanghai Pharmaceuticals Holding Co., Ltd. 41 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

84/100

Pipeline Velocity

0/100

Mech. Concentration

3/100

Completion Rate

77/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arcus Biosciences logo

Arcus Biosciences

2 programs

Phase 1A

Adnexus, A Bristol-Myers Squibb R&D Company

1 program

Phase 1S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1S

Sentynl Therapeutics, Inc.

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical3

Bevacizumab

Bio-Thera Solutions

Allogeneic Cytomegalovirus-Specific T Cells

Queensland Institute of Medical Research

Ferumoxytol Non-Stoichiometric Magnetite

OHSU Knight Cancer Institute

Phase 162

Hydroxychloroquine

Alnylam Pharmaceuticals

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Zimberelimab

Arcus Biosciences

Afatinib

Boehringer Ingelheim

Phase 2132

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cemiplimab

Regeneron

Basiliximab

Novartis

Antineoplaston A10

Burzynski Research Institute

Avelumab

EMD Serono

Phase 318

Cediranib

AstraZeneca

Enzastaurin

Eli Lilly

Cilengitide

EMD Serono

Nivolumab

Bristol-Myers Squibb

Carmustine

Melissa K Accordino

Approved41

Talazoparib

Pfizer

Memantine

AbbVie

Pioglitazone

Takeda

Methimazole

Viking Therapeutics, Inc.

Abemaciclib

Eli Lilly

Analysis

Modality Breakdown

80%

Small molecule

210 of 261 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody2911%Protein / enzyme83%Vaccine62%Cell therapy52%Peptide1<1%RNA therapy1<1%Other1<1%

Small molecule leads; the ring shows all 261 classified programs, each share of the total. Modality classified for 100% of 293 pipeline programs.

Analysis

Trial Status

276

clinical trials

Completed170 · 62%
Terminated40 · 14%
Unknown status31 · 11%
Active, not recruiting13 · 5%
Withdrawn10 · 4%
Recruiting10 · 4%
Other2 · 1%

Clinical Trials

Trial Activity

276 trials

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Recruiting·BBeyondBio Inc.·Phase 1·NCT05769660·12 enrolled
NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme
Recruiting·PPoznan University of Medical Sciences·N/A·NCT06271421·100 enrolled
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Recruiting·SStanford University·Phase 1·NCT05474378·39 enrolled
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Recruiting·JJenKem Technology Co., Ltd.·Phase 2·NCT06595186·25 enrolled
Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Recruiting·EEver Supreme Bio Technology Co., Ltd.·Phase 2·NCT04115761·24 enrolled
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Recruiting·NNaviFUS Corporation·Phase 3·NCT06496971·32 enrolled
Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Recruiting·CCentre Antoine Lacassagne·Phase 1/2·NCT02331498·51 enrolled
Advancing Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning - a Prospective Study
Recruiting·WWashington University School of Medicine·N/A·NCT05864976·100 enrolled
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Recruiting·National Cancer Institute (NCI)·N/A·NCT00083512·200 enrolled
FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM
Recruiting·BBoston Scientific Corporation·Phase 1·NCT05303467·36 enrolled
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Active, not recruiting·UUniversitätsmedizin Mannheim·Phase 3·NCT02685605·314 enrolled
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Active, not recruiting·EEpitopoietic Research Corporation·Phase 2·NCT01903330·84 enrolled
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
Active, not recruiting·PPolaris Group·Phase 2·NCT04587830·100 enrolled
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Active, not recruiting·National Cancer Institute (NCI)·Phase 2/3·NCT02152982·447 enrolled
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Active, not recruiting·CCNS Pharmaceuticals, Inc.·Phase 2·NCT04762069·210 enrolled
Page 1 of 19

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)